PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

Bar Kaufman; Tarek Taha; Orli Abramov; Yaniv Zohar; Kamel Mhameed; Ofir Cohen; Angel Porgador; Moshe Elkabets; Salem Billan

doi:10.1038/s41698-024-00620-y

PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

Bar Kaufman, Tarek Taha, Orli Abramov, Yaniv Zohar, Kamel Mhameed, Ofir Cohen, Angel Porgador, Moshe Elkabets, Salem Billan

The Shraga Segal Department of Microbiology and Immunology

Research output: Contribution to journal › Article › peer-review

Abstract

Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands’ functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

Original language	English
Article number	126
Journal	npj Precision Oncology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/s41698-024-00620-y
State	Published - 1 Dec 2024

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41698-024-00620-y

Cite this

@article{017f3fddc2ba495dbd216ff806065f0b,

title = "PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC",

abstract = "Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands{\textquoteright} functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.",

author = "Bar Kaufman and Tarek Taha and Orli Abramov and Yaniv Zohar and Kamel Mhameed and Ofir Cohen and Angel Porgador and Moshe Elkabets and Salem Billan",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

day = "1",

doi = "10.1038/s41698-024-00620-y",

language = "English",

volume = "8",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

AU - Kaufman, Bar

AU - Taha, Tarek

AU - Abramov, Orli

AU - Zohar, Yaniv

AU - Mhameed, Kamel

AU - Cohen, Ofir

AU - Porgador, Angel

AU - Elkabets, Moshe

AU - Billan, Salem

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands’ functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

AB - Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands’ functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

UR - http://www.scopus.com/inward/record.url?scp=85195270152&partnerID=8YFLogxK

U2 - 10.1038/s41698-024-00620-y

DO - 10.1038/s41698-024-00620-y

M3 - Article

C2 - 38830971

AN - SCOPUS:85195270152

SN - 2397-768X

VL - 8

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 126

ER -

PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this